Investors Take Note: Class Action Filed Against Applied Therapeutics

Legal Alert for Shareholders — The Schall Law Firm, a nationwide firm focusing on shareholder rights, has announced a class action lawsuit against Applied Therapeutics, Inc. (“Applied Therapeutics” or “the Company”) APLT. The firm alleges the Company violated §§10(b) and 20(a) of the Securities Exchange Act of 1934 along with Rule 10b-5, as defined by the U.S. Securities and Exchange Commission.

Class Period Details — Investors who bought securities from the Company between January 3, 2024, and December 2, 2024, inclusive (the “Class Period”), are urged to reach out to the firm before February 18, 2025.

Steps to Participation — If you are a shareholder who has experienced a loss, click here to participate.

Contact Information — You may also contact Brian Schall of the Schall Law Firm at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, by calling 310-301-3335. Additional contact options include the firm’s website at www.schallfirm.com or via email at bschall@schallfirm.com.

Understanding Class Status — Currently, the class in this case has not been certified. Until certification takes place, you do not have legal representation. If you choose to take no action at this time, you can remain an absent class member.

Allegations Against Applied Therapeutics — The complaint alleges that the Company made false and misleading statements regarding its drug candidate, govorestat. Specifically, Applied Therapeutics reportedly failed to follow proper trial protocols and clinical practices. These lapses raised concerns that the FDA might reject their trial data upon submission with the rovorestat NDA. Consequently, statements made by the Company during this period were deemed false and misleading. Following the revelation of these facts, investors faced significant financial losses.

Join the Legal Action — Those affected are encouraged to join the case to recover their losses.

About the Firm — The Schall Law Firm represents investors globally and specializes in securities class action lawsuits and shareholder rights issues.

Disclaimer — This announcement may be considered Attorney Advertising in certain jurisdictions based on applicable laws and ethical guidelines.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241218156371/en/